GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Carl Zeiss Meditec AG (OTCPK:CZMWY) » Definitions » Research & Development

Carl Zeiss Meditec AG (Carl Zeiss Meditec AG) Research & Development : $384 Mil (TTM As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Carl Zeiss Meditec AG Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Carl Zeiss Meditec AG's Research & Development for the three months ended in Dec. 2023 was $96 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was $384 Mil.

Carl Zeiss Meditec AG Research & Development Historical Data

The historical data trend for Carl Zeiss Meditec AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carl Zeiss Meditec AG Research & Development Chart

Carl Zeiss Meditec AG Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 190.87 257.72 273.02 288.48 372.76

Carl Zeiss Meditec AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.81 90.20 97.93 99.98 95.75

Carl Zeiss Meditec AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $384 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG  (OTCPK:CZMWY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Carl Zeiss Meditec AG Research & Development Related Terms

Thank you for viewing the detailed overview of Carl Zeiss Meditec AG's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Carl Zeiss Meditec AG (Carl Zeiss Meditec AG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Carl Zeiss Meditec AG (OTCPK:CZMWY) » Definitions » Research & Development
Comparable Companies
XTER:1SXP XTER:FIE XTER:GXI FRA:PHH2 ISRG XPAR:EL BDX TSE:7741 XSWX:ALC RMD OCSE:COLO B WST TSE:4543 XSWX:STMN XPAR:DIM BAX HOLX COO TSE:7733 TSE:6869
Traded in Other Exchanges
CZMWF:USA 1AFX:Italy AFXd:UK 0DHC:UK AFX:Germany AFX:Austria
Address
Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Website
https://www.zeiss.com
Carl Zeiss Meditec is one of the largest medical technology companies in the world and it operates in two segments: Ophthalmic devices and Microsurgery. OPT, which made up 75% of sales in 2022, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.